Join to View Full Profile
3181 Sw Sam Jackson Park Rd, L952Portland, OR 97239
Phone+1 503-494-5596
Fax+1 503-494-3688
Dr. Druker is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1981 - 1984
University of California San Diego School of MedicineClass of 1981
Certifications & Licensure
OR State Medical License 1993 - 2027
WA State Medical License 2022 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- America's Top Doctors Castle Connolly, 2007-2014
Clinical Trials
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Publications & Presentations
PubMed
- Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, Deedra Nicolet, Krzysztof Mrózek
American Journal of Hematology. 2026-07-02 - 1 citationsmutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Haematologica. 2026-05-01 - Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.Uma Borate, Cristina E Tognon, Yazan F Madanat, Shikha Misra, Andy Kaempf
Blood Neoplasia. 2026-05-01
Journal Articles
- CRISPR-Cas9–Mediated Saturated Mutagenesis Screen Predicts Clinical Drug Resistance with Improved AccuracyRichard D Press, Brian J Druker, Michael R Green, Proceedings of the National Academy of Sciences
Press Mentions
Scammers Hijacked the Identity of a Famous Oregon Cancer Doctor to Pitch Ivermectin OnlineJune 11th, 2026- New Cancer Research Tool Predicts Patient Survival at Single-Cell ResolutionApril 21st, 2026
- Billion-Dollar Moves and More: Oncology Deals in the SpotlightSeptember 23rd, 2025
Grant Support
- Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaOREGON HEALTH & SCIENCE UNIVERSITY2022–2027
- Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaOREGON HEALTH & SCIENCE UNIVERSITY2022–2027
- Contribution of Inflammation to the Pathogenesis of RUNX1-FPDMMOREGON HEALTH & SCIENCE UNIVERSITY2017–2027
- Contribution of Inflammation to the Pathogenesis of RUNX1-FPDMMOREGON HEALTH & SCIENCE UNIVERSITY2017–2027
- Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School StudentsOREGON HEALTH & SCIENCE UNIVERSITY2018–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
